Opioids
Opioid receptors and the cellular mechanism of analgesia, how structure and kinetics explain the differences between agents, the mechanisms behind the adverse effects, active metabolites and genetic variation, tolerance and dependence, and the principles of antagonism.
By the end of this page you should be able to
- Describe the opioid receptors, their endogenous ligands and the cellular effects of receptor activation.
- Classify opioids by origin and by activity at the receptor, and explain partial agonism and mixed agonist-antagonist action.
- Explain how lipid solubility, ionisation, protein binding and metabolism account for the differences between agents.
- Describe the mechanism of each major adverse effect, including respiratory depression.
- Explain the importance of active metabolites and of genetic variation in metabolism.
- Describe tolerance, dependence, withdrawal and opioid-induced hyperalgesia, and the principles of reversal.
Receptors and mechanism
Three receptors matter: mu, kappa and delta. All are G protein coupled receptors linked to inhibitory G proteins. Activation inhibits adenylate cyclase and lowers cyclic AMP, closes presynaptic voltage-gated calcium channels so that less neurotransmitter is released, and opens postsynaptic potassium channels so that the cell hyperpolarises. The net effect is reduced neuronal excitability and transmission.
The endogenous ligands are the endorphins (mainly mu), enkephalins (delta) and dynorphins (kappa).
Analgesia arises at several levels: peripherally on sensitised nociceptors, in the dorsal horn where opioids inhibit transmission from primary afferents to second-order neurones, and supraspinally, where activation in the periaqueductal grey and rostral ventromedial medulla recruits descending inhibition. There is also a powerful affective component in the limbic system, which is why patients often say the pain is still there but no longer matters.
Kappa agonism gives spinal analgesia with dysphoria, sedation and diuresis, which is why selective kappa agonists have not succeeded clinically. Functional selectivity between G protein and arrestin signalling is the basis of attempts to separate analgesia from respiratory depression.
Classifying the drugs
- By origin: naturally occurring (morphine, codeine), semisynthetic (diamorphine, oxycodone, buprenorphine), and synthetic (the phenylpiperidines such as pethidine and fentanyl, methadone, tramadol, tapentadol).
- Full agonists: morphine, oxycodone, fentanyl and its congeners, methadone, codeine. A full agonist has no ceiling to its analgesic or respiratory effect.
- Partial agonist: buprenorphine has very high receptor affinity but submaximal efficacy, so it has a ceiling for respiratory depression, a long duration because it dissociates slowly, and can displace a full agonist and precipitate withdrawal.
- Mixed agonist-antagonist: pentazocine and nalbuphine (kappa agonist with mu antagonism) cause dysphoria and have a ceiling effect.
- Antagonists: naloxone (short-acting, poor oral bioavailability because of first-pass metabolism, which is why it is used parenterally and why oral naloxone combinations act on the gut) and naltrexone (oral, long-acting).
- Atypical agents: tramadol and tapentadol combine weak mu agonism with monoamine reuptake inhibition, which adds serotonin toxicity risk, seizure risk and interactions with antidepressants. Methadone adds NMDA antagonism and blocks potassium channels, prolonging the QT interval, and has a long and variable half-life. Pethidine has an active metabolite, norpethidine, that is proconvulsant and accumulates in renal impairment, and it interacts dangerously with monoamine oxidase inhibitors.
Kinetics and why agents differ
- Lipid solubility sets speed of onset. Fentanyl is highly lipid soluble and crosses into the brain within a minute or two; morphine is relatively hydrophilic, so its effect lags behind its plasma concentration by 15 to 30 minutes. That lag is the commonest cause of stacked dosing and late sedation.
- Redistribution, not elimination, ends the effect of a single dose of a lipophilic drug: fentanyl is taken up into muscle and fat, so a single dose is brief, but repeated doses or an infusion saturate those compartments and the context-sensitive half-time lengthens dramatically.
- Oral bioavailability is limited by first-pass metabolism, which is extensive for morphine (hence the large difference between oral and parenteral potency) and less so for oxycodone and methadone.
- Routes: intramuscular and subcutaneous absorption is unreliable in shock, so titrated intravenous administration is preferred; transdermal patches take many hours to reach steady state and are unsuitable for acute pain.
- Metabolism is mainly hepatic: morphine is glucuronidated (little affected by cytochrome interactions), while codeine, oxycodone, tramadol, fentanyl and methadone involve cytochrome P450 enzymes and so are subject to inhibitors and inducers.
- Active metabolites are a frequent exam theme. Morphine-6-glucuronide is a more potent analgesic than morphine and is renally cleared, so it accumulates in renal impairment and causes delayed, prolonged sedation; morphine-3-glucuronide is not analgesic and may be neuroexcitatory. Norpethidine is proconvulsant. Fentanyl has no active metabolite, which is one reason it is preferred in renal failure.
- Pharmacogenetics: codeine is a prodrug needing CYP2D6 to form morphine. Poor metabolisers (a substantial minority of some populations) get little analgesia, while ultra-rapid metabolisers produce much more morphine than expected, which is the basis of its restriction in children and in breastfeeding. Tramadol is activated by the same enzyme.
Adverse effects and their mechanisms
- Respiratory depression: mu receptors in the pre-Botzinger complex and nearby medullary centres reduce respiratory rate and blunt the ventilatory response to carbon dioxide, and later to hypoxia. The pattern is a falling rate with preserved or large tidal volumes, then irregular breathing and apnoea. Sedation always precedes dangerous respiratory depression, which is why the conscious state is the most useful monitor, and why pulse oximetry alone, especially with supplemental oxygen, gives false reassurance.
- Sedation and, in excess, miosis through the Edinger-Westphal nucleus (pethidine is an exception because of its antimuscarinic action).
- Nausea and vomiting by direct stimulation of the chemoreceptor trigger zone, by delayed gastric emptying and by vestibular sensitisation.
- Constipation through mu receptors in the myenteric plexus: reduced propulsive motility and increased sphincter tone, with increased water absorption. Tolerance to this effect barely develops, so it must be anticipated and treated.
- Histamine release from mast cells, which is a direct, non-immune effect, greatest with morphine and codeine: itch, flushing, urticaria along a vein and occasionally hypotension or bronchospasm. True allergy is rare, and a history of itch is not an allergy.
- Cardiovascular: mild vasodilatation and bradycardia through reduced sympathetic tone and vagal effects, which can matter in the already hypotensive patient. Pethidine is the exception, causing tachycardia.
- Other: urinary retention (increased detrusor and sphincter tone), rigidity and cough suppression with rapid high-dose potent agents, endocrine effects with chronic use (hypogonadism), immune modulation, and QT prolongation with methadone.
Tolerance, dependence and antagonism
Tolerance is a reduced effect from the same exposure over time, from receptor phosphorylation and desensitisation, arrestin recruitment and internalisation, and adaptive upregulation of cyclic AMP signalling and of NMDA pathways. It develops fastest for analgesia, euphoria, sedation and respiratory depression, and hardly at all for constipation and miosis, which is clinically useful. Cross-tolerance between opioids is incomplete, which is why rotating to a different agent can restore effect.
Physical dependence is an adaptive state revealed by withdrawal when the drug is stopped or an antagonist is given: yawning, lacrimation, sweating, mydriasis, piloerection, cramps, diarrhoea, aching and agitation. It is rarely life threatening in adults but dangerous in the neonate. It is not the same as addiction, a behavioural syndrome of compulsive use despite harm involving the mesolimbic dopamine pathway.
Opioid-induced hyperalgesia is a paradoxical increase in pain sensitivity with prolonged exposure, mediated partly by NMDA receptor and descending facilitatory pathways. It looks like tolerance but gets worse, not better, with more drug.
Antagonism follows competitive pharmacology. Naloxone has high mu affinity but a shorter duration than most of the agonists it reverses, so a patient who wakes can become narcosed again as it wears off: observation is timed from the last dose of antagonist, not the first, and an infusion may be needed. Giving more than is needed to restore adequate ventilation removes analgesia and precipitates withdrawal, agitation, vomiting and a catecholamine surge; the aim is adequate ventilation, not a fully awake patient. Buprenorphine, with its high affinity, is relatively resistant to reversal. For regimens, routes and quantities, check the Australian Medicines Handbook or your local toxicology guideline.
Making the answer flow
- Start with the receptor and the cellular mechanism, then place each clinical effect at an anatomical site; the adverse effects then come out in an organised way rather than as a list.
- Use lipid solubility and redistribution to explain the difference between fentanyl and morphine, and context-sensitive half-time for infusions.
- Name the active metabolites and say which are renally cleared.
- When asked about reversal, make the point about the duration mismatch and the aim of restoring ventilation rather than full wakefulness.
Where marks are lost
- Saying opioids blunt the hypoxic drive before the carbon dioxide response; the carbon dioxide response goes first.
- Describing opioid itch and flushing as an allergy.
- Forgetting that codeine and tramadol are prodrugs dependent on CYP2D6.
- Saying tolerance develops to constipation; it does not.
- Forgetting the duration mismatch between naloxone and long-acting agonists.
Where this meets intensive care
- Morphine-6-glucuronide is active and renally cleared, so morphine causes prolonged sedation and respiratory depression in kidney injury; fentanyl has no active metabolites but accumulates with infusion.
- Remifentanil is broken down by non-specific plasma and tissue esterases, so its context-sensitive half-time is short and constant whatever the infusion duration.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the opioid receptors and what happens when one is activated.
Show answer
- Mu, kappa and delta; all G protein coupled through inhibitory G proteins.
- Reduced adenylate cyclase and cyclic AMP; presynaptic calcium channel closure reducing transmitter release; postsynaptic potassium channel opening with hyperpolarisation.
- Endogenous ligands: endorphins, enkephalins, dynorphins.
- Mu mediates most analgesia, euphoria, respiratory depression and constipation; kappa gives spinal analgesia with dysphoria and sedation.
- 2.
Where in the nervous system do opioids produce analgesia?
Show answer
- Peripheral sensitised nociceptors.
- Dorsal horn: inhibition of transmission from primary afferent to second order neurone, pre and postsynaptically.
- Periaqueductal grey and rostral ventromedial medulla: activation of descending inhibition.
- Limbic system: alteration of the affective response to pain.
- 3.
Why does fentanyl act faster than morphine, and why does a fentanyl infusion behave differently from a single dose?
Show answer
- Fentanyl is far more lipid soluble and largely unionised, so it crosses the blood brain barrier rapidly; morphine is hydrophilic with a delay of 15 to 30 minutes to peak effect.
- A single fentanyl dose is terminated by redistribution into muscle and fat, not elimination.
- Repeated doses or infusion saturate peripheral compartments, so context-sensitive half-time lengthens and the effect outlasts the infusion.
- Practical consequence: titrate morphine allowing for its lag, and anticipate prolonged effect after a long fentanyl infusion.
- 4.
Which opioid metabolites matter and why?
Show answer
- Morphine-6-glucuronide: more potent than morphine, renally cleared, accumulates in renal impairment causing delayed sedation.
- Morphine-3-glucuronide: not analgesic, possibly neuroexcitatory.
- Norpethidine: proconvulsant, long half-life, accumulates with repeated dosing and in renal failure.
- Codeine and tramadol are prodrugs needing CYP2D6; fentanyl has no active metabolite, so it is favoured in renal failure.
- 5.
Explain the mechanism of opioid respiratory depression and how you would monitor for it.
Show answer
- Mu receptors in medullary respiratory centres including the pre-Botzinger complex reduce rate and blunt the ventilatory response to carbon dioxide, later to hypoxia.
- Falling respiratory rate with preserved tidal volume, then irregular breathing and apnoea.
- Sedation precedes it, so conscious level is the best early monitor; capnography detects hypoventilation earlier than oximetry.
- Supplemental oxygen maintains saturation while carbon dioxide rises, which masks deterioration.
- Risk factors: extremes of age, obstructive sleep apnoea, renal and hepatic impairment, other sedatives, opioid-naive patients.
- 6.
What is buprenorphine and why does it behave unusually?
Show answer
- Partial mu agonist with very high affinity and slow dissociation, plus kappa antagonism.
- Ceiling effect for respiratory depression but relatively resistant to reversal by an antagonist.
- Can displace a full agonist and precipitate withdrawal in a dependent patient.
- Long duration; sublingual and transdermal routes used because of high first-pass metabolism.
- 7.
Distinguish tolerance, dependence, addiction and opioid-induced hyperalgesia.
Show answer
- Tolerance: reduced effect with continued exposure; receptor desensitisation and downstream adaptation; incomplete cross-tolerance between agents.
- Physical dependence: adaptive state with a withdrawal syndrome on cessation or antagonism.
- Addiction: compulsive use despite harm, a behavioural syndrome involving mesolimbic dopamine.
- Hyperalgesia: increased pain sensitivity with prolonged exposure, NMDA mediated, worsened by dose escalation.
- 8.
Describe the pharmacology of naloxone.
Show answer
- Competitive antagonist with high affinity at mu and lower affinity at kappa and delta.
- Rapid onset parenterally; extensive first-pass metabolism, so oral bioavailability is poor and oral forms act on the gut.
- Duration shorter than most agonists it reverses, so re-sedation can occur and an infusion may be needed; observe from the last dose.
- Excess causes acute withdrawal, agitation, vomiting, hypertension, tachycardia and, rarely, pulmonary oedema; aim for adequate ventilation.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 11 in the other subjects
- Physiology: Blood pressure control and regional circulations
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.